Bone Cancer Diagnosis Market Size Share and Industry Outlook to 2028

SKU: DMMD4129 | Last Updated On: Jan 20 2022 | No. of Pages: 180 | Available Formats

> Global Bone Cancer Diagnosis Market Expected to reach a high CAGR By 2028: DataM Intelligence

Global Bone Cancer Diagnosis Market is Segmented By Disease Type(Osteosarcoma, Chondrosarcoma, Ewing’s sarcoma, Spindle cell sarcoma and Chordoma), By Diagnosis type(MRI, CT Scan, X-ray, Bone scan and Biopsy), By End-User(Hospitals, Diagnostic Centers, Cancer Research Centers and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Market Overview

The global bone cancer diagnosis market is estimated to reach at a CAGR of 5.6 % during the forecast period (2021-2028). 

Bone cancer is rare cancer that develops when cells in the bone begin to grow out of control. The pelvis, long bones in the arms and legs are the most usually affected. Bone cancer is extremely rare, accounting for less than 1% of all cancers. Bone tumours that aren't cancerous are far more common than cancerous ones.

Source: DataM Intelligence Analysis (2020)

Market Dynamics

The factors affecting the global bone cancer diagnosis market are the rising population of children and young adults and technological advancements.

The rising population of children and young adults is expected to drive the global bone cancer diagnosis market

According to the American Cancer Society, between the ages of 10 and 30, most osteosarcomas develop in children, teenagers, and young adults. Although teenagers are the most typically affected age group, osteosarcoma can affect anyone at any age. Osteosarcomas affect about one out of every ten adults over the age of 60. About 2% of childhood cancers are osteosarcomas. Children with osteosarcoma aged 0 to 14 had a 5-year survival rate of 68 per cent. The 5-year survival rate for teenagers aged 15 to 19 is 67 per cent. The overall 5-year survival rate for people of all ages is 74 per cent if osteosarcoma is discovered and treated before it has progressed outside the location where it began. The 5-year survival rate is 66 per cent if the disease has migrated outside of the bones and into surrounding tissues or organs, as well as regional lymph nodes. The 5-year survival rate is 27 per cent if cancer has progressed to other regions of the body. Teenage boys are the most common victims of osteosarcoma. Osteosarcoma patients are typically tall for their age, implying that the disease is caused by rapid bone growth. Osteosarcoma is more common in children who have inherited one of the uncommon cancer syndromes. Retinoblastoma (a malignant tumour that forms in the retina, a portion of the eye, generally in children under the age of 2) and Li-Fraumeni syndrome (a type of inherited genetic mutation or change in a person's genes) are two of these syndromes.

There are 1.2 billion teenagers in the world today, accounting for one-sixth of the worldwide population. This figure is predicted to climb through 2050, especially in low- and middle-income nations, where about 90% of children aged 10 to 19 live. Hence, the increasing incidence of osteosarcoma and the rising population of teenagers is estimated to drive the global bone cancer diagnosis market.

 Technological advancements are expected to drive the global bone cancer diagnosis market in the forecast period

In the field of research, nanotechnology is rapidly developing and has yielded ground-breaking technologies for diagnosing and treating OSA. A variety of nanomaterials have been developed in this regard for the targeted therapy of OSA with the least damage to normal human cells. Nanoparticles (NPs) have a wide range of uses in OSA diagnosis and therapy as engineered nanomaterials. This is owing to their unique structure, high drug encapsulation efficiency, and high bioavailability. NPS can transfer numerous chemicals, medicines, tiny molecules, peptides, nucleic acids, and even vaccinations to the target region as promising nanocarriers.

A new type of CT scan known as gemstone spectral CT (GSCT) has recently gained much attention. To address the limitations of standard CT, GSCT has a high capacity for material disintegration and monochromatic pictures. Created up-conversion nanoparticles are based on lutecium (Lu). Lu-based UCNPs outperformed iohexol (contrast agent) in spectral CT and maybe a better spectral CT contrast agent for diagnosing OSA. Nano platform tests reveal that in vitro and in vivo GSCT can provide higher diagnostic elucidation and differentiate the OSA from the surrounding bones.

In 2017, GE Healthcare received 510(k) clearance from the US Food and Drug Administration (FDA) for GSI Stream on Revolution CT (computed tomography).

Misdiagnosis of bone cancer is expected to hamper the market growth

According to the Bone Cancer Research Trust (BCRT) organisation, only 42% of patients diagnosed with osteosarcoma live for five years after diagnosis. This emphasises the necessity of recognizing the disease as soon as possible, as a late cancer diagnosis is more likely to reduce the patient's chances of survival. Unfortunately, misdiagnosis of bone cancer is still widespread, which is perhaps why survival rates have remained stable for the past 25 years. If a patient’s osteosarcoma is localised (meaning it hasn't spread to other parts), their long-term survival prospects are fairly excellent (70-75 per cent). However, by the time the disease is recognized, it has spread to other parts of the body in about 15-20% of patients. The long-term survival probability for osteosarcoma that has progressed to the lungs or other bones drops substantially to barely 30%. As a result, it is critical to diagnose this type of bone cancer as soon as feasible.

COVID-19 Impact Analysis

COVID-19 has affected the healthcare industry moderately. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. The COVID-19 epidemic has disrupted cancer care, causing delays in diagnosis and treatment, as well as the suspension of clinical trials. As a result, healthcare institutions are urgently rearranging cancer services to ensure that patients continue to receive critical care while limiting their exposure to the SARS-CoV-2 virus. This has moderately affected the global bone cancer diagnosis market due to limitations to avoid transmission of COVID.

Segment Analysis

Based on type, the Magnetic resonance imaging (MRI) segment is expected to hold the largest market share

MRIs use radio waves and strong magnets instead of x-rays to obtain detailed images of soft tissues in the body, avoiding radiation. Before the scan, a contrast material called gadolinium is often injected into a vein to help see details better. An MRI is frequently used to provide a more thorough look at a bone mass that has been seen on an x-ray. MRIs can typically determine whether the mass is a tumour, an infection, or some other sort of bone injury. MRIs can also show the marrow inside bones and the soft tissues around the tumour, including neighbouring blood arteries and nerves, which can assist assess the exact extent of a tumour. Small bone tumours can be seen on MRIs several inches apart from the main tumour (called skip metastases). When it comes to surgery, knowing the extent of osteosarcoma is crucial.

MRI is the best method for local staging of bone malignancies because of its excellent evaluation of bone marrow. It provides a realistic representation of bone marrow and soft tissue involvement. MRI can detect specific tissue components that are important for the characterization of a bone lesion using a variety of approaches. Because many of these cancers are treated before surgery, MRI can monitor post-chemotherapy alterations using customized sequences. New and more sophisticated methodologies using fast and ultrafast MRI are being tested to improve the accuracy of therapy response assessment.

On March 4, 2021, At the commencement of the 2021 European Congress of Radiology, Hitachi Medical Systems launched two new permanent open MRI systems. SynergyDrive workflow solution is installed on both platforms.

Geographical Analysis

North America region accounted for the largest market share in the global bone cancer diagnosis market

The increasing incidence of osteosarcoma and companies launching new devices for cancer diagnosis is expected to increase this region's market growth.

In the United States, roughly 1,000 new instances of osteosarcoma are diagnosed each year. The majority of these are children and teenagers. Primary bone sarcoma will be diagnosed in an expected 3,610 people in the United States this year (2,100 men and boys and 1,510 women and girls). Around 400 of these instances are expected to occur in people aged 15 to 19 by 2020.

This disease is expected to kill 2,060 people this year (1,190 men and boys and 870 women and girls).

On February 17, 2020, Hyperfine, a New York City-based firm with offices in St Guilford and New York City, has received FDA approval for the first MRI scanner that can be wheeled to the patient's bedside.

In 2018, The Ingenia Ambition X 1.5T MR was released by Ingenia, a global pioneer in health technology. This exciting new advancement is the newest addition to the Ingenia MRI portfolio, which includes completely digital MRI equipment, healthcare informatics, and a variety of maintenance and life cycle services for integrated solutions that enable a faster, smarter, and simpler approach to a confident diagnosis. For a step-change in productivity, Ingenia Ambition X combines fully sealed BlueSeal magnet technology with workflow advancements.

Source: DataM Intelligence Analysis (2020)

Competitive Landscape

The global cancer diagnosis market is highly competitive with technological advancements and increased medical device launches with advanced technology by companies.

Some of the key players in the global bone cancer diagnosis market are Siemens Healthineers, Varex Imaging, Philips Healthcare, GE Healthcare, FUJIFILM Healthcare, Konica Minolta, Hologic, Leica Biosystems, Toshiba, and Shimadzu Corporation

Siemens Healthineers

Overview: Siemens Healthineers helps healthcare organizations worldwide add value by empowering them to enhance precision medicine, alter care delivery, improve patient experience, and digitalize healthcare. The company is a global pioneer in medical technology, is continually developing new products and services in its key areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine. Siemens Healthineers is also expanding its digital health and enterprise services offerings.

Product Portfolio: Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine. For example, through MAGNETOM Free. Max MRI's reach is being expanded by breaking down barriers. The world's first 80 cm bore sets a new standard in patient comfort in areas where patients have previously experienced discomfort. MAGNETOM Free eliminates infrastructure as a barrier to MRI.

Key Development: on August 2, 2020, Varian Medical Systems, Inc. was acquired by Siemens Healthineers. With this acquisition, Siemens Healthineers now expects to spread the development of a unique, highly integrated portfolio of imaging, laboratory diagnostics, artificial intelligence, and treatment services for cancer patients.

Why Purchase the Report?

  • Visualize the composition of the global bone cancer diagnosis market Segmentation by Disease Type, Diagnosis type and End-User highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global bone cancer diagnosis market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global bone cancer diagnosis market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global bone cancer diagnosis market report would provide access to an approx. 45+ market data table, 40+ figures and 180 pages. 

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Bone Cancer Diagnosis Market - By Disease Type

  • Osteosarcoma
  • Chondrosarcoma
  • Ewing’s sarcoma
  • Spindle cell sarcoma
  • Chordoma

Global Bone Cancer Diagnosis Market - By Diagnosis type

  • MRI
  • CT Scan
  • X-ray
  • Bone scan
  • Biopsy

Global Bone Cancer Diagnosis Market - By End-User

  • Hospitals
  • Diagnostic Centers
  • Cancer Research Centers
  • Other

Global Bone Cancer Diagnosis Market - By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa

Trending Topics

Breast Cancer Screening and Diagnostic Techniques Market

Contrast Media Injectors Market

Table of Contents

  1. Global Bone Cancer Diagnosis Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global Bone Cancer Diagnosis Market – Market Definition and Overview

  3. Global Bone Cancer Diagnosis Market – Executive Summary

    1. Market Snippet By Disease Type
    2. Market Snippet By Diagnosis type
    3. Market Snippet By End-User
    4. Market Snippet By Region
  4. Global Bone Cancer Diagnosis Market -Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. Rising population of children and young adults
        2. Technological advancements
      2. Restraints:
        1. Misdiagnosis of bone cancer
      3. Opportunity
      4. Impact Analysis
  5. Global Bone Cancer Diagnosis Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Epidemiology Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
    5. Regulatory Analysis
    6. Reimbursement Analysis
    7. Unmet Needs
  6. Global Bone Cancer Diagnosis Market – COVID-19 Analysis

    1. Analysis of Covid-19 on the Market
      1. Before COVID-19 Market Scenario
      2. Present COVID-19 Market Scenario
      3. After COVID-19 or Future Scenario
    2. Pricing Dynamics Amid Covid-19
    3. Demand-Supply Spectrum
    4. Government Initiatives Related to the Market During Pandemic
    5. Manufacturers Strategic Initiatives
    6. Conclusion 
  7. Global Bone Cancer Diagnosis Market – By Disease Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
      2. Market Attractiveness Index, By Disease Type Segment
    2. Osteosarcoma
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Chondrosarcoma
    4. Ewing’s sarcoma
    5. Spindle cell sarcoma
    6. Chordoma
  8. Global Bone Cancer Diagnosis Market – By Diagnosis type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis type
      2. Market Attractiveness Index, By Diagnosis type
    2. MRI*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. CT Scan
    4. X-ray
    5. Bone scan
    6. Biopsy
  9. Global Bone Cancer Diagnosis Market – By End-User

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
      2. Market Attractiveness Index, By End-User Segment
    2. Hospitals*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Diagnostic Centers
    4. Cancer Research Centers
    5. Others
  10. Global Bone Cancer Diagnosis Market – By Region

    1. Introduction
      1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  11. Global Bone Cancer Diagnosis Market – Competitive Landscape

    1. Key Developments and Strategies
    2. Company Share Analysis
    3. Product Benchmarking
  12. Global Bone Cancer Diagnosis Market - Company Profiles

    1. Siemens Healthineers*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Varex Imaging
    3. Philips Healthcare
    4. GE Healtcare
    5. FUJIFILM Healthcare
    6. Konica Minolta
    7. Hologic
    8. Leica Biosystems
    9. Toshiba
    10. Shimadzu Corporation(*LIST NOT EXHAUSTIVE)
  13. Global Bone Cancer Diagnosis Market – DataM  

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

List of Tables

Table 01 Global Bone Cancer Diagnosis Market Value, By Disease Type, 2020, 2024 & 2028($ Million)

Table 02 Global Bone Cancer Diagnosis Market Value, By Diagnosis type, 2020, 2024 & 2028($ Million)

Table 03 Global Bone Cancer Diagnosis Market Value, By End-User, 2020, 2024 & 2028($ Million)

Table 04 Global Bone Cancer Diagnosis Market Value, By Disease Type, 2020, 2024 & 2028($ Million)

Table 05 Global Bone Cancer Diagnosis Market Value, By Disease Type, 2019-2028 ($ Million)

Table 06 Global Bone Cancer Diagnosis Market Value, By Diagnosis type, 2020, 2024 & 2028($ Million)

Table 07 Global Bone Cancer Diagnosis Market Value, By Diagnosis type, 2019-2028 ($ Million)

Table 08 Global Bone Cancer Diagnosis Market Value, By End-User, 2020, 2024 & 2028($ Million)

Table 09 Global Bone Cancer Diagnosis Market Value, By End-User, 2019-2028 ($ Million)

Table 10 Global Bone Cancer Diagnosis Market Value, By Region, 2020, 2024 & 2028($ Million)

Table 11  Global Bone Cancer Diagnosis Market Value, By Region, 2019-2028 ($ Million)

Table 12  North America Bone Cancer Diagnosis Market Value, By Disease Type,2019-2028 ($ Million)

Table 13  North America Bone Cancer Diagnosis Market Value, By Diagnosis type, 2019-2028 ($ Million)

Table 14  North America Bone Cancer Diagnosis Market Value, By End-User, 2019-2028 ($ Million)

Table 15  North America Bone Cancer Diagnosis Market Value, By Country, 2019-2028 ($ Million)

Table 16  South America Bone Cancer Diagnosis Market Value, By Disease Type,2019-2028 ($ Million)

Table 17  South America Bone Cancer Diagnosis Market Value, By Diagnosis type, 2019-2028 ($ Million)

Table 18 South America Bone Cancer Diagnosis Market Value, By End-User, 2019-2028 ($ Million)

Table 19  South America Bone Cancer Diagnosis Market Value, By Country, 2019-2028 ($ Million)

Table 20 Europe Bone Cancer Diagnosis Market Value, By Disease Type,2019-2028 ($ Million)

Table 21  Europe Bone Cancer Diagnosis Market Value, By Diagnosis type, 2019-2028 ($ Million)

Table 22 Europe Bone Cancer Diagnosis Market Value, By End-User, 2019-2028 ($ Million)

Table 23 Europe Bone Cancer Diagnosis Market Value, By Country, 2019-2028 ($ Million)

Table 24 Asia-Pacific Bone Cancer Diagnosis Market Value, By Disease Type,2019-2028 ($ Million)

Table 25 Asia-Pacific Bone Cancer Diagnosis Market Value, By Diagnosis type, 2019-2028 ($ Million)

Table 26 Asia-Pacific Bone Cancer Diagnosis Market Value, By End-User, 2019-2028 ($ Million)

Table 27 Asia-Pacific Bone Cancer Diagnosis Market Value, By Country, 2019-2028 ($ Million)

Table 28 Middle East & Africa Bone Cancer Diagnosis Market Value, By Disease Type,2019-2028 ($ Million)

Table 29 Middle East & Africa Bone Cancer Diagnosis Market Value, By Diagnosis type, 2019-2028 ($ Million)

Table 30 Middle East & Africa Bone Cancer Diagnosis Market Value, By End-User, 2019-2028 ($ Million)

Table 31  Siemens Healthineers: Overview

Table 32 Siemens Healthineers: Product Portfolio

Table 33 Siemens Healthineers: Key Developments

Table 34 Varex Imaging: Overview

Table 35 Varex Imaging: Product Portfolio

Table 36 Varex Imaging: Key Developments

Table 37 Philips Healthcare: Overview

Table 38 Philips Healthcare: Product Portfolio

Table 39 Philips Healthcare: Key Developments

Table 40 GE Healtcare: Overview

Table 41  GE Healtcare: Product Portfolio

Table 42 GE Healtcare: Key Developments

Table 43 FUJIFILM Healthcare: Overview

Table 44 FUJIFILM Healthcare: Product Portfolio

Table 45 FUJIFILM Healthcare: Key Developments

Table 46 Konica Minolta: Overview

Table 47 Konica Minolta: Product Portfolio

Table 48 Konica Minolta: Key Developments

Table 49 Hologic Overview

Table 50 Hologic: Product Portfolio

Table 51  Hologic: Key Developments

Table 52 Leica Biosystems: Overview

Table 53 Leica Biosystems: Product Portfolio

Table 54 Leica Biosystems: Key Developments

Table 55 Toshiba: Overview

Table 56 Toshiba: Product Portfolio

Table 57 Toshiba: Key Developments

Table 58 Shimadzu Corporation: Overview

Table 59 Shimadzu Corporation: Product Portfolio

Table 60 Shimadzu Corporation: Key Developments

   List of Figures

Figure 01 Global Bone Cancer Diagnosis Market Share, By Disease Type, 2020 & 2028(%) By Disease Type, 2020

Figure 02 Global Bone Cancer Diagnosis Market Share, By Diagnosis type, 2020 & 2028(%)

Figure 03 Global Bone Cancer Diagnosis Market Share, By End-User, 2020 & 2028(%)

Figure 04 Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 05 Global Bone Cancer Diagnosis Market Y-o-Y Growth, By Disease Type, 2020-2028 (%)

Figure 06 Osteosarcoma: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 07 Chondrosarcoma: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 08 Ewing’s sarcoma: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 09 Spindle cell sarcoma: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 10 Chordoma: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 11 Global Bone Cancer Diagnosis Market Y-o-Y Growth, By Diagnosis type, 2020-2028 (%)

Figure 12 MRI: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 13 CT scan: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 14 X-ray: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 15 Bone scan: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 16 Biopsy: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 17 Global Bone Cancer Diagnosis Market Y-o-Y Growth, By End-User, 2020-2028 (%)

Figure 18 Hospitals: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 19 Diagnostic Centers: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 20 Cancer Research Centers: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 21 Other: Global Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 22 Global Bone Cancer Diagnosis Market Y-o-Y Growth, By Region, 2020-2028 (%)

Figure 23 North America Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 24 North America Bone Cancer Diagnosis Market Share, By Disease Type, 2020 & 2028(%)

Figure 25 North America Bone Cancer Diagnosis Market Share, By Diagnosis type, 2020 & 2028(%)

Figure 26 North America Bone Cancer Diagnosis Market Share, By End-User, 2020 & 2028(%)

Figure 27 North America Bone Cancer Diagnosis Market Share, By Country, 2020 & 2028(%)

Figure 28 South America Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 29 South America Bone Cancer Diagnosis Market Share, By Disease Type, 2020 & 2028(%)

Figure 30 South America Bone Cancer Diagnosis Market Share, By Diagnosis type, 2020 & 2028(%)

Figure 31 South America Bone Cancer Diagnosis Market Share, By End-User, 2020 & 2028(%)

Figure 32 South America Bone Cancer Diagnosis Market Share, By Country, 2020 & 2028(%)

Figure 33 Europe Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 34 Europe Bone Cancer Diagnosis Market Share, By Disease Type, 2020 & 2028(%)

Figure 35 Europe Bone Cancer Diagnosis Market Share, By Diagnosis type, 2020 & 2028(%)

Figure 36 Europe Bone Cancer Diagnosis Market Share, By End-User, 2020 & 2028(%)

Figure 37 Europe Bone Cancer Diagnosis Market Share, By Country, 2020 & 2028(%)

Figure 38 Asia-Pacific Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 39 Asia-Pacific Bone Cancer Diagnosis Market Share, By Disease Type, 2020 & 2028(%)

Figure 40 Asia-Pacific Bone Cancer Diagnosis Market Share, By Diagnosis type, 2020 & 2028(%)

Figure 41 Asia-Pacific Bone Cancer Diagnosis Market Share, By End-User, 2020 & 2028(%)

Figure 42 Asia-Pacific Bone Cancer Diagnosis Market Share, By Country, 2020 & 2028(%)

Figure 43 Middle East & Africa Bone Cancer Diagnosis Market Value, 2019-2028 ($ Million)

Figure 44 Middle East & Africa Bone Cancer Diagnosis Market Share, By Disease Type, 2020 & 2028(%)

Figure 45 Middle East & Africa Bone Cancer Diagnosis Market Share, By Diagnosis type, 2020 & 2028(%)

Figure 46 Middle East & Africa Bone Cancer Diagnosis Market Share, By End-User, 2020 & 2028(%)

Figure 47 Siemens Healthineers: Financials

Figure 48 Varex Imaging: Financials

Figure 49 Philips Healthcare: Financials

Figure 50 GE Healtcare: Financials

Figure 51 FUJIFILM Healthcare: Financials

Figure 52 Konica Minolta: Financials

Figure 53 Hologic: Financials

Figure 54 Leica Biosystems: Financials

Figure 55 Toshiba: Financials

Figure 56 Shimadzu Corporation: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest